Medical technology company RaySearch laboratories AB (RaySearch) (STO:RAYB) announced on Monday the selection by the Shanghai Proton and Heavy Ion Centre (SPHIC) of the treatment planning system RayStation from the company, for its planned operations in the New Pudong district of Shanghai, the People's Republic of China.

Reportedly, the parties will cooperate to achieve Chinese market clearance for proton and heavy ion treatment planning. This order is the first of its kind outside of Europe and Japan, where RaySearch is the market leader among comparable centres. Also, SPHIC will provide technical support and data for the RayStation regulatory submission process which will begin in 2020.

According to the company, the full RayStation installation includes modules for proton and carbon ion pencil beam scanning with robust biological optimisation using both the local effect model and microdosimetric-kinetic models for radiobiological effect.

This order has a total value of about EUR1.5m, including service agreement, of which only a minor part is expected be recognised as revenues within the fourth quarter of 2019.

RaySearch Laboratories develops software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch.